retatrutide news today recency 3 ADA 2026: Revolution New Retatrutide Phase 3 Trial

Ortega AL, Mena S, Estrela JM

Research shows that Allulose powerfully increases the body's GLP-1 secretion

Cholewiska E, Jukiewicz J, Majewski M, Smagie R, Listos P, Fotschki B

Four vials, four reconstitutions, four to five daily injections, four potential sources of quality issues, and twelve possible interaction pairs to troubleshoot if something goes wrong

Glossary AUD alcohol-use disorder CD Chron's disease CLBP chronic low back pain CNPV Commissioner's National Priority Voucher CV cardiovascular CVD cardiovascular disease FDA Food and Drug Administration GIP glucose-dependent insulinotropic polypeptide GLP-1 glucagon-like peptide-1 GLP-1s glucagon-like peptide-1 receptor agonists HTN hypertension MACE major adverse cardiovascular events MASH metabolic dysfunction-associated steatohepatitis OA osteoarthritis OSA obstructive sleep apnea PsA psoriatic arthritis PSO psoriatic arthritis SC subcutaneous SGLT2i sodium-glucose co-transporter 2 inhibitor T1DM type 1 diabetes mellitus T2DM type 2 diabetes mellitus UC ulcerative colitis U.S

"Look at the results objectively at every stage: If you're gaining weight back, it's an indication your body needs the higher dose," she says